Markers of Bone and Cartilage Turnover

被引:13
作者
Woitge, Henning W. [1 ]
Seibel, Markus J. [2 ]
机构
[1] ANZAC Res Inst, Bone Res Program, Sydney, NSW, Australia
[2] ANZAC Res Inst, Sydney, NSW 2139, Australia
关键词
bone; cartilage; metabolism; markers; osteoporosis; arthritis; OLIGOMERIC MATRIX PROTEIN; RESISTANT ACID-PHOSPHATASE; VERTEBRAL FRACTURE RISK; C-TERMINAL TELOPEPTIDE; II COLLAGEN; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; ALKALINE-PHOSPHATASE; JOINT FLUID; PROTEOGLYCAN FRAGMENTS;
D O I
10.1055/s-0043-106438
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past few decades, scientists have been trying to identify tissue-specific markers that would help to better understand the pathogenesis of bone and cartilage diseases and could be used clinically for the screening, diagnosis and followup of bone or joint diseases. Historically, only a few components known to be involved in bone, mineral or cartilage turnover were available for this purpose (e.g., urine hydroxyproline, serum and urine calcium and phosphate levels). However, since most if not all of these substances have wider biological functions beyond bone, mineral and cartilage metabolism, their clinical value as tissue-specific markers was limited. Hence, there was a need to identify more specific indices of bone and cartilage metabolism. Since the 1980s, a number of collagenous and non-collagenous breakdown products as well as cell-specific enzymes have been discovered and developed into markers of musculoskeletal tissue metabolism. This review describes their chemical and biological function, available analytical methods and possible clinical applications.
引用
收藏
页码:454 / 469
页数:16
相关论文
共 161 条
[21]   LOCALIZATION OF BONE SIALOPROTEIN (BSP) EXPRESSION TO SITES OF MINERALIZED TISSUE FORMATION IN FETAL-RAT TISSUES BY INSITU HYBRIDIZATION [J].
CHEN, JK ;
SHAPIRO, HS ;
WRANA, JL ;
REIMERS, S ;
HEERSCHE, JNM ;
SODEK, J .
MATRIX, 1991, 11 (02) :133-143
[22]   Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases [J].
Chen, TL ;
Berenson, J ;
Vescio, R ;
Swift, R ;
Gilchick, A ;
Goodin, S ;
LoRusso, P ;
Ma, PM ;
Ravera, C ;
Deckert, F ;
Schran, H ;
Seaman, J ;
Skerjanec, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11) :1228-1236
[23]   Biological markers for osteoarthritis: an update [J].
Chevalier, X ;
Conrozier, T .
JOINT BONE SPINE, 2005, 72 (02) :106-109
[24]  
Christgau S, 2004, MENOPAUSE, V11, P508, DOI 10.1097/01.WCB.0000121484.18437.98
[25]  
Christgau S, 2004, CLIN EXP RHEUMATOL, V22, P36
[26]  
CHRISTIANSEN C, 1987, LANCET, V1, P1106
[27]   BONE TURNOVER IN POSTMENOPAUSAL OSTEOPOROSIS - EFFECT OF CALCITONIN TREATMENT [J].
CIVITELLI, R ;
GONNELLI, S ;
ZACCHEI, F ;
BIGAZZI, S ;
VATTIMO, A ;
AVIOLI, LV ;
GENNARI, C .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 82 (04) :1268-1274
[28]  
Cloos PAC., 1998, Bone, V23, pF440
[29]   Analysis of human bone sialoprotein in normal and pathological tissues using a monoclonal antibody (BSP 1.2 mab) [J].
Cogan, G ;
Bansal, AK ;
Ibrahim, S ;
Zhu, BQ ;
Goldberg, HA ;
Ganss, B ;
Cheifetz, S ;
Armbruster, FP ;
Sodek, J .
CONNECTIVE TISSUE RESEARCH, 2004, 45 (01) :60-71
[30]   Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs [J].
Cummings, SR ;
Karpf, DB ;
Harris, F ;
Genant, HK ;
Ensrud, K ;
LaCroix, AZ ;
Black, DM .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (04) :281-289